Home / Health / New Drug Halts High Blood Pressure in Kidney Patients
New Drug Halts High Blood Pressure in Kidney Patients
30 May
Summary
- Experimental drug lorundrostat significantly reduced systolic blood pressure.
- The pill also cut key markers of kidney damage in patients.
- An FDA decision on the drug is anticipated by December 2026.
Mineralys Therapeutics has announced promising results for its experimental drug, lorundrostat, in treating high blood pressure in patients with chronic kidney disease (CKD).
The once-daily pill, lorundrostat, demonstrated a statistically significant and clinically meaningful reduction in systolic blood pressure. In a late-stage trial involving 800 patients, those with CKD experienced an average reduction of 9.6 mmHg compared to a placebo over 12 weeks.
Further analysis revealed that lorundrostat also positively impacted kidney health. In a subgroup of CKD patients with elevated levels, the drug reduced albumin, a key indicator of kidney damage, by over half. This finding is critical as CKD is closely linked to hypertension, affecting millions worldwide.
The drug's mechanism involves blocking aldosterone production, a hormone associated with elevated blood pressure. Lorundrostat is currently under review by the U.S. Food and Drug Administration (FDA), with an expected decision by December 2026. The field is becoming increasingly competitive with recent approvals of similar aldosterone-blocking drugs.
